DK1870109T3 - Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus - Google Patents

Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus Download PDF

Info

Publication number
DK1870109T3
DK1870109T3 DK07019279.4T DK07019279T DK1870109T3 DK 1870109 T3 DK1870109 T3 DK 1870109T3 DK 07019279 T DK07019279 T DK 07019279T DK 1870109 T3 DK1870109 T3 DK 1870109T3
Authority
DK
Denmark
Prior art keywords
vaccine composition
pigs
vaccine
mycoplasma hyopneumoniae
challenge
Prior art date
Application number
DK07019279.4T
Other languages
English (en)
Inventor
Wumin Li
Zhichang Xu
Hsien-Jue Chu
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32680190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1870109(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK1870109T3 publication Critical patent/DK1870109T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (19)

1. Vaccinesammensætning til immunisering af et dyr mod infektion med Mycoplasma hyopneumoniae og porcin circovirus (PCV), som omfatter en immuniserende mængde af Mycoplasma hyopneumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); en adjuvansblanding omfattende en acrylsyrepolymer og en blanding af en metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer; og et farmaceutisk acceptabelt bærestof, hvilken vaccinesammensætning fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae efter en enkelt indgivelse.
2. Vaccinesammensætning ifølge krav 1, hvor adjuvansblandingen består af en acrylsyrepolymer og en blanding af en metaboliserbar olie, der omfatter en eller flere terpencarbonhydrider og en polyoxyethylen-polyoxypropylen-blokcopolymer i et forhold på ca. 1:25 til 1:50 acrylsyrepolymer til metaboliserbar olie/polyoxyethylen-polyoxypropylen-blokcopolymer-blanding.
3. Vaccinesammensætning ifølge krav 1, hvor adjuvansblandingen omfatter ca. 1-25% v/v af vaccinesammensætningen.
4. Vaccinesammensætning ifølge krav 3, hvor acrylsyrepolymeren er til stede i en endelig koncentration på ca. 1 % v/v og terpencarbonhydri-der/polyoxyethylen-polyoxypropylen-blokcopolymer-blandingen er til stede i en endelig koncentration på ca. 5 % til 10 % v/v.
5. Vaccinesammensætning ifølge krav 3, hvor adjuvansblandingen omfatter ca. 2 % -15 % v/v af vaccinesammensætningen.
6. Vaccinesammensætning ifølge krav 5, hvor adjuvansblandingen omfatter ca. 5 % -12 % v/v af vaccinesammensætningen.
7. Vaccinesammensætning ifølge krav 1, hvor den metaboliserbare olie er squalan eller squalen.
8. Vaccinesammensætning ifølge krav 6 eller krav 7, hvor acrylsyrepolyme-ren er en carbomer.
9. Vaccinesammensætning ifølge et hvilket som helst af kravene 1-8, yderligere omfattende mindst et bakterin eller oprenset toksoid udvalgt fra gruppen bestående af Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae og leptospira-bakterier.
10. Vaccinesammensætning ifølge et hvilket som helst af kravene 1-8, yderligere omfattende et bakterie- eller virusantigen udvalgt blandt et eller flere af følgende: Haemonphilus parasuis, PRRSV, Erysipelothrix rhusiopathiae, Pasteurella multiocida og Bordetella bronchiseptica.
11. Vaccinesammensætning omfattende en immuniserende mængde af et Mycoplasma hyopneumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); en adjuvansblanding omfattende en acrylsyrepolymer og en blanding af metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer; og et farmaceutisk acceptabelt bærestof, til anvendelse til beskyttelse af et dyr mod sygdom forårsaget af Mycoplasma hyopneumoniae og porcin circovirus (PCV), hvor vaccinesammensætningen, fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae-infektion efter en enkelt indgivelse.
12. Vaccinesammensætning til anvendelse ifølge krav 11, hvor den immuniserende mængde af bakterierne er ca. 1 x 108 til 3 x 1011 MHDCE/ml.
13. Vaccinesammensætning til anvendelse ifølge krav 12, hvor den immuniserende mængde af bakterierne er ca. 1 x 109 til 3 x 109 MHDCE/ml.
14. Vaccinesammensætning til anvendelse ifølge krav 11, hvor indgivelsesmåden i indgivelsestrinnet er intramuskulær, subkutan, intraperitoneal, aerosol, oral eller intranasal.
15. Vaccinesammensætning til anvendelse ifølge krav 11, hvor adjuvans-blandingen består af en acrylsyrepolymer og en blanding af en metaboliser- bar olie, der omfatter en eller flere terpencarbonhydrider og en polyoxyethy-len-polyoxypopylen-blokcopolymer, der er til stede i en endelig koncentration på ca. 1 -25% v/v.
16. Vaccinesammensætning til anvendelse ifølge krav 15, hvor acrylsyre-polymeren af adjuvansblandingen er en carbomer.
17. Vaccinesammensætning til anvendelse ifølge krav 15, hvor den metabo-liserbare olie i adjuvansblandingen er en terpencarbonhydrid udvalgt fra gruppen af squalan og squalen.
18. Vaccine sammensætning til anvendelse ifølge et hvilket som helst af kravene 11-17, yderligere omfattende co-administration af mindst et yderligere bakterin udvalgt fra gruppen bestående af Haemonphilus parasuis, Pasteu-rella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bor-detella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae og leptospira-bakterier.
19. Vaccine sammensætning til immunisering af et dyr mod infektion med Mycoplasma hyopneumoniae og porcin circovirus (PCV), hvilken vaccinesammensætning omfatter en immuniserende mængde af Mycoplasma hyop-neumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); og et adjuvanssystem omfattende en acrylsyrepolymer, en metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer i form af en olie-i-vand-emulsion; hvilken vaccinesammensætning fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae efter en enkelt indgivelse.
DK07019279.4T 2002-05-17 2003-05-14 Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus DK1870109T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/150,597 US7018638B2 (en) 2000-12-19 2002-05-17 Mycoplasma hyopneumoniae bacterin vaccine
EP03813041.5A EP1506006B1 (en) 2002-05-17 2003-05-14 Improved combined vaccine against mycoplasma hyopneumoniae and porcine viruses

Publications (1)

Publication Number Publication Date
DK1870109T3 true DK1870109T3 (da) 2016-04-25

Family

ID=32680190

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07019279.4T DK1870109T3 (da) 2002-05-17 2003-05-14 Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus

Country Status (20)

Country Link
US (4) US7018638B2 (da)
EP (2) EP1870109B1 (da)
JP (2) JP2006515304A (da)
KR (1) KR101056622B1 (da)
CN (1) CN1305524C (da)
AR (1) AR039545A1 (da)
AU (1) AU2003303129B2 (da)
BR (1) BR0310082A (da)
CL (1) CL2010000397A1 (da)
DK (1) DK1870109T3 (da)
ES (2) ES2431988T3 (da)
HK (1) HK1111103A1 (da)
HR (1) HRP20041068B1 (da)
ME (1) ME00569B (da)
MX (1) MXPA04011218A (da)
NZ (1) NZ537014A (da)
RS (1) RS54390B1 (da)
TW (1) TWI320715B (da)
WO (1) WO2004058142A2 (da)
ZA (1) ZA200410153B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
CA2187535C (en) * 1994-04-11 2011-09-13 Jon B. Korshus Borrelia burgdorferi bacterin
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
AU3198200A (en) * 1999-03-08 2000-09-28 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Prrsv vaccines
DK2251419T3 (da) * 1999-04-22 2012-07-02 Us Agriculture Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
CA2571452A1 (en) * 2004-06-18 2006-01-26 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US7632636B2 (en) * 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) * 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US20060251827A1 (en) * 2005-05-09 2006-11-09 Applied Materials, Inc. Tandem uv chamber for curing dielectric materials
PT1904631E (pt) 2005-06-24 2012-07-16 Univ Minnesota Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EA014028B1 (ru) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
KR101436794B1 (ko) 2005-12-29 2014-09-04 베링거잉겔하임베트메디카인코퍼레이티드 다가 ｐｃｖ2 면역원성 조성물 및 이러한 조성물의 제조방법
MX356667B (es) 2005-12-29 2018-06-08 Boehringer Ingelheim Vetmedica Inc Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
BRPI0710550A2 (pt) * 2006-04-10 2011-08-16 Intervet Int Bv uso de uma dose imunogênica de material imunogênico de mycoplasma hyopneumoniae e uma dose imunogênica de vìrus de prrs atenuado vivo, kit de vacina, e, método para a vacinação de porcos
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2094872T4 (da) * 2006-12-15 2020-05-18 Boehringer Ingelheim Animal Health Usa Inc Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
AU2012261741B2 (en) * 2007-11-06 2016-02-25 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
UA98812C2 (ru) 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
WO2009103037A1 (en) * 2008-02-15 2009-08-20 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN101363865B (zh) * 2008-05-26 2013-03-06 北京庄笛浩禾生物医学科技有限公司 一种猪蓝耳病毒胶体金检测试纸条、其制备方法及其应用
CN102119033B (zh) * 2008-06-25 2015-04-08 布拉施生物技术有限责任公司 用于增强促生长素抑制素免疫原性的组合物和方法
US20100003278A1 (en) * 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
CN102316895A (zh) * 2008-08-25 2012-01-11 贝林格尔.英格海姆维特梅迪卡有限公司 抗高致病性猪生殖与呼吸综合征(hp prrs)的疫苗
KR101825697B1 (ko) 2009-02-10 2018-02-05 노파르티스 아게 감소된 양의 스쿠알렌을 포함하는 인플루엔자 백신
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2808285C (en) * 2010-08-27 2016-09-06 Intervet International B.V. Potency test for vaccine formulations
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
CN101954079B (zh) * 2010-09-21 2012-11-28 江苏省农业科学院 猪支原体肺炎活疫苗的疫苗佐剂及其制备方法和应用
MY186535A (en) 2011-02-17 2021-07-26 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
CN103370077B (zh) 2011-02-17 2016-10-26 贝林格尔.英格海姆维特梅迪卡有限公司 猪繁殖与呼吸综合征病毒的商业化规模生产方法
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2737059A1 (en) 2011-07-29 2014-06-04 Boehringer Ingelheim Vetmedica GmbH Novel prrs virus inducing type i interferon in susceptible cells
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
CN103157100B (zh) * 2011-12-08 2014-09-24 普莱柯生物工程股份有限公司 副猪嗜血杆菌病、猪链球菌病二联灭活疫苗及其制备方法
US9474692B2 (en) 2012-01-13 2016-10-25 Boehringer Ingelheim Vetmedica Gmbh Kit for the preparation of a vaccinating agent
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
CN103908665B (zh) * 2013-01-05 2016-05-25 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103071151B (zh) * 2013-01-17 2014-07-23 江苏省农业科学院 猪支原体肺炎疫苗专用稀释剂及其制备方法
CN103961695B (zh) * 2013-02-06 2016-09-07 普莱柯生物工程股份有限公司 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CN104096222B (zh) * 2013-04-08 2016-09-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
WO2014182872A1 (en) * 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
CA2924228C (en) 2013-10-02 2024-01-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN104857508B (zh) * 2014-02-21 2018-03-16 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
AU2016354532B2 (en) 2015-11-13 2020-08-06 Targan, Inc. Automatic system and method for injecting a substance into an animal
CN111346224B (zh) 2018-12-24 2023-12-08 洛阳赛威生物科技有限公司 一种免疫佐剂组合物及其制备方法和应用
CN112618710B (zh) * 2019-09-24 2023-09-29 华南理工大学 一种植物糖原猪口服接种疫苗纳米佐剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
ES2097840T3 (es) * 1987-11-03 1997-04-16 Syntex Inc Adyuvante de vacuna que comprende un tetrapoliol.
ZA906806B (en) * 1989-08-31 1991-06-26 Ici Australia Operations Plants
WO1991018627A1 (en) * 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
KR100374434B1 (ko) * 1994-05-10 2003-06-09 와이어쓰 변형된소호흡관련합포체바이러스(brsv)생백신조성물
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine

Also Published As

Publication number Publication date
US20070134269A1 (en) 2007-06-14
JP2013189438A (ja) 2013-09-26
ES2569063T3 (es) 2016-05-06
EP1506006B1 (en) 2013-07-31
US20030017171A1 (en) 2003-01-23
WO2004058142A3 (en) 2004-11-04
AU2003303129B2 (en) 2009-10-08
US7959927B2 (en) 2011-06-14
NZ537014A (en) 2009-09-25
EP1870109B1 (en) 2016-03-16
US20100062018A1 (en) 2010-03-11
KR101056622B1 (ko) 2011-08-16
HRP20041068B1 (hr) 2018-10-05
HK1111103A1 (zh) 2008-08-01
MXPA04011218A (es) 2005-02-14
AR039545A1 (es) 2005-02-23
TW200306854A (en) 2003-12-01
TWI320715B (en) 2010-02-21
JP5700861B2 (ja) 2015-04-15
ZA200410153B (en) 2014-07-30
CN1305524C (zh) 2007-03-21
US20060228373A1 (en) 2006-10-12
RS99704A (en) 2006-12-15
AU2003303129A1 (en) 2004-07-22
WO2004058142A2 (en) 2004-07-15
US7622124B2 (en) 2009-11-24
RS54390B1 (sr) 2016-04-28
CN1652817A (zh) 2005-08-10
KR20050007402A (ko) 2005-01-17
EP1506006A2 (en) 2005-02-16
BR0310082A (pt) 2007-04-10
EP1870109A1 (en) 2007-12-26
ES2431988T3 (es) 2013-11-29
HRP20041068A2 (en) 2004-12-31
JP2006515304A (ja) 2006-05-25
ME00569A (en) 2011-12-20
US7169394B2 (en) 2007-01-30
CL2010000397A1 (es) 2010-10-15
US7018638B2 (en) 2006-03-28
ME00569B (me) 2011-12-20

Similar Documents

Publication Publication Date Title
DK1870109T3 (da) Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus
US7666439B2 (en) Mycoplasma hyopneumoniae bacterin vaccine